NASDAQ:ZBIO Zenas BioPharma (ZBIO) Stock Price, News & Analysis $15.41 -0.30 (-1.91%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Zenas BioPharma Stock (NASDAQ:ZBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zenas BioPharma alerts:Sign Up Key Stats Today's Range$15.02▼$15.9950-Day Range$9.14▼$16.4552-Week Range$5.83▼$26.25Volume164,595 shsAverage Volume156,428 shsMarket Capitalization$644.60 millionP/E RatioN/ADividend YieldN/APrice Target$36.67Consensus RatingBuy Company Overview Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. Read More Zenas BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreZBIO MarketRank™: Zenas BioPharma scored higher than 35% of companies evaluated by MarketBeat, and ranked 733rd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingZenas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZenas BioPharma has only been the subject of 2 research reports in the past 90 days.Read more about Zenas BioPharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Zenas BioPharma is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zenas BioPharma is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZenas BioPharma has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zenas BioPharma's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ZBIO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZenas BioPharma does not currently pay a dividend.Dividend GrowthZenas BioPharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ZBIO. News and Social Media2.7 / 5News Sentiment0.78 News SentimentZenas BioPharma has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Zenas BioPharma this week, compared to 11 articles on an average week.Search InterestOnly 1 people have searched for ZBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zenas BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders16.50% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Zenas BioPharma's insider trading history. Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zenas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ZBIO Stock News Headlines3 Highly Shorted Stocks That Could Be the Next Wall Street SensationsAugust 2 at 1:44 PM | msn.comZenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MSJuly 28, 2025 | seekingalpha.comWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the company I called “dramatically undervalued” has broken out of a multi-year discount zone. The re-pricing has begun. My free cash flow model nailed this call. And here’s the kicker: several other top gold developers are trading at similar deep discounts right now.August 4 at 2:00 AM | Golden Portfolio (Ad)Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharmaJuly 3, 2025 | tipranks.comZenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2025 | globenewswire.comZBIO DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 ...June 17, 2025 | stockhouse.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 17, 2025 | prnewswire.comZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 16, 2025 | globenewswire.comSee More Headlines ZBIO Stock Analysis - Frequently Asked Questions How have ZBIO shares performed this year? Zenas BioPharma's stock was trading at $7.90 on January 1st, 2025. Since then, ZBIO shares have increased by 95.1% and is now trading at $15.41. How were Zenas BioPharma's earnings last quarter? Zenas BioPharma, Inc. (NASDAQ:ZBIO) released its earnings results on Thursday, May, 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.35. The company had revenue of $10 million for the quarter, compared to analyst estimates of $5 million. When did Zenas BioPharma IPO? Zenas BioPharma (ZBIO) raised $225 million in an IPO on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share. How do I buy shares of Zenas BioPharma? Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zenas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas BioPharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), Biosig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI). Company Calendar Last Earnings5/15/2025Today8/04/2025Next Earnings (Estimated)8/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:ZBIO Previous SymbolNASDAQ:ZBIO CIK1953926 WebN/A Phone(857) 271-2954FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Zenas BioPharma$36.67 High Price Target$45.00 Low Price Target$30.00 Potential Upside/Downside+137.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.47 Quick Ratio6.47 Sales & Book Value Annual Sales$5 million Price / Sales128.92 Cash FlowN/A Price / Cash FlowN/A Book Value$7.48 per share Price / Book2.06Miscellaneous Outstanding Shares41,830,000Free Float34,931,000Market Cap$644.60 million OptionableN/A BetaN/A Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Create New Advertiser | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.